Why the Pro Medicus (ASX:PME) share price is up 3% in a week

It's been a good few days for the provider of medical imaging software. We take a closer look

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price continues its run into the green today.

Pro Medicus shares are changing hands at $59.60 apiece in afternoon trading, up 1.2% on the day.

Let's take a look at the tailwinds behind the company's share price.

But first, a quick recap on Pro Medicus

Pro Medicus is a provider of medical imaging software to clinics and hospitals.

Its footprint is in Australia, North America, and Europe, supplying radiology information and imaging systems to these markets.

At the time of writing, Pro Medicus has a market capitalisation of $6.1 billion.

What has Pro Medicus been up to lately?

Pro Medicus shares have set two all-time highs recently, including today, when prices reached an intraday high of $60.55.

The momentum behind the company's share price has been gathering steam since the beginning of the year.

Back in January, the company announced it had signed a 7-year contract with Salt Lake City company Intermountain Healthcare.

According to Pro Medicus, the deal will yield a total of $40 million spread over the 7 years.

Following this, the company also announced that its US subsidiary Visage Imaging had confirmed a collaboration with the University of Vermont.

Under the agreement, Pro Medicus will install and roll out its systems in six hospitals under the University's control.

Moreover, it was revealed back on 3 June that Pro Medicus entered into an agreement with the US research giant Mayo Clinic through Visage.

The focus of this deal is to develop and commercialise Pro Medicus' artificial intelligence algorithm, the Visage AI Accelerator platform.

Since this fundamental momentum began in January, Pro Medicus shares have climbed 74% this year to date.

This has extended into the previous 5 trading sessions, in which the company has walked a further 3.5% into the green.

Therefore, while there has been no market sensitive information from the company since June, it stands to reason that investors continue to buy Pro Medicus shares on the back of these advancements in the company's growth engine.

Pro Medicus share price snapshot

The Pro Medicus share price has posted an impressive return of 140% over the previous 12 months.

This has outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of 21% over the same period.

The company also pays a 14 cents per share dividend, giving a current yield of 0.22%.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Share Market News

Netwealth Group announces $101 million compensation after First Guardian collapse

Netwealth Group will pay $101 million in compensation, posting a $71 million 1H26 NPAT impact following the First Guardian collapse.

Read more »

A young female ASX investor sits at her desk with her fists raised in excitement as she reads about rising ASX share prices on her laptop.
Broker Notes

Two ASX 200 stocks with buy recommendations from Ord Minnett

These two stocks appear to have strong upside.

Read more »

a hand reaches out with australian banknotes of various denominations fanned out.
Dividend Investing

These 2 ASX dividend shares are great buys right now

These defensive names look like strong picks today.

Read more »

Four piles of coins, each getting higher, with trees on them.
Growth Shares

2 ASX 200 shares that could be top buys for growth

These two businesses have an exciting future.

Read more »

Two IT professionals walk along a wall of mainframes in a data centre discussing various things
Technology Shares

This ASX 200 share is being labelled one of the market's most undervalued by brokers

NextDC shares have pulled back sharply, but brokers believe the long-term growth story remains firmly on track.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Market News

5 things to watch on the ASX 200 on Thursday

Here's what to look out for on the local market today.

Read more »

Person pointing finger on on an increasing graph which represents a rising share price.
Broker Notes

Experts rate these 2 ASX growth shares as buys this month!

These businesses could deliver good returns in the coming years.

Read more »

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was another woeful day for investors this Wednesday.

Read more »